Ms. Ieshia L Jones, CSFA Surgery Medicare: Not Enrolled in Medicare Practice Location: 10175 County Road 229, Oxford, FL 34484 Phone: 352-346-4945 |
News Archive
Speaking in Rome, Italy today on the occasion of World Osteoporosis Day, International Osteoporosis Foundation (IOF) CEO Patrice McKenney called for individuals and governments around the globe to join the fight against osteoporosis. "Osteoporosis is a common but devastating disease which we cannot afford to ignore. Immediate measures must be taken to reduce the burden of osteoporotic fractures through prevention, early recognition of fracture risk, and appropriate proven treatment for those in need," she urged.
Neuralstem, Inc. announced that it has filed an Investigational New Drug (IND) application with the United States Food and Drug Administration (FDA) to begin a Phase I safety clinical trial for chronic spinal cord injury with its spinal cord stem cells. This multicenter Phase I safety trial will enroll a total of 16 long-term, or chronic, spinal cord injury patients, with an American Spinal Injury Association (ASIA) Grade A level of impairment, one-to-two years post-injury.
Methotrexate and the more expensive mycophenolate mofetil performed similarly in a head-to-head clinical trial that compared the two drugs for treating noninfectious uveitis, an eye disease that accounts for up to 15% of blindness in the U. S.
Conatus Pharmaceuticals Inc. announced today 24-week interim results from a clinical trial with CTS-1027 in combination with Peginterferon Alpha-2a and ribavirin in a treatment experienced, hepatitis C virus null-responder patient population.
› Verified 3 days ago